Navigation Links
Selexis and NKT Therapeutics Enter Into Research Services Agreement
Date:9/1/2009

GENEVA, Sept. 1 /PRNewswire/ -- Selexis SA ("Selexis") and NKT Therapeutics, Inc. ("NKTT") announce today that they have entered into a research services agreement whereby Selexis will screen antibody variants and generate high performance CHO-based production cell lines using their novel platform named INTEGRA-D2M(TM). The Selexis INTEGRA-D2M(TM) platform enables the rapid isolation of production cell lines concomitant with the selection of lead compounds from libraries of protein variants expressed in Chinese Hamster Ovary (CHO) cells. Utilizing INTEGRA-D2M(TM), protein variant libraries of sizes larger than 10exp3 can be screened to identify lead compounds in less than 9 weeks. The selected CHO-based protein variant expressing clone can then be used directly for cGMP manufacturing.

"We are excited about the partnership with NKTT, who are recognized as leaders in the biology and therapeutic applications for modulating Natural Killer T cells," said Dr. Igor Fisch, CEO and co-founder of Selexis SA. "Our novel and powerful INTEGRA-D2M(TM) platform, is able to support NKTT in rapidly making their final product decision while we also develop and deliver a high-performance production cell line ready for cGMP manufacturing."

"We greatly appreciate working with the team at Selexis and utilizing their powerful technology platform," adds Dr. Alem Truneh, Chief Scientific Officer and co-founder of NKT Therapeutics.

About Selexis INTEGRA-D2M(TM) Platform

Developed by Selexis over the last 2 years, the Selexis INTEGRA-D2M(TM) platform is a simple, non-robotic based approach enabling the screening of protein libraries in CHO cells. Such stable CHO-based libraries are developed in less than 9 weeks and enable the rapid selection of the best product candidates with respect to functionality (i.e. binding assay, neutralization assay) and titers (with reduced future COGS). The platform is also directly linked to the generation of high producing cell clones (for cGMP manufacturing) that are then generated in 12 weeks. The benefits of this approach are better preclinical decisions, dramatically shortened timelines and lower overall operational costs.

About Selexis:

Selexis is a privately held Swiss biotechnology company dedicated to the development of innovative technologies and expert services that enable significant improvements in the time, effort, and costs required to develop and maintain high-performance mammalian cell lines used in the expression of pharmaceutically relevant proteins (i.e. targets, MAbs, rProteins). The company's core intellectual property portfolio is based on the discovery and application of novel DNA based elements that control the dynamic organization of chromatin within all mammalian cells - Selexis Genetic Elements(TM). Selexis has further developed platforms, to include: Selexis SUREtech Vectors(TM), Selexis SUREfection(TM) Selexis SURE Cell Line Development(TM) and Selexis INTEGRA-D2M(TM).

About NKT Therapeutics Inc.

NKT Therapeutics, Inc. is a privately held biotechnology company focused on developing therapeutics based on unique immune cells called natural killer T (NKT) cells. The company's mission is to use its expertise to develop a pipeline of first-in-class NKT-based therapeutics to treat asthma, cancer, autoimmune and infectious diseases. For more information on the company, please visithttp://www.nktrx.com/.


'/>"/>
SOURCE Selexis SA
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Selexis Now Offering Rapid-Development of Human Cell Line With FDA Approval Pedigree
2. Prime Therapeutics Receives TIPPS Certification
3. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
4. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
5. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
6. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
7. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
8. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
9. Prime Therapeutics Announces URAC Accreditation
10. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
11. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... BSI and Brenntag Canada ... States and Canada for distribution of their natural fruits and beverage colorants ... is an exciting addition to our Life Sciences product portfolio,” said Steve Brauer, President ...
(Date:12/5/2016)... ... 2016 , ... Sideline Products is a Southern York County Pennsylvania-based premier designer ... and the horse. Smaller saddles can pinch and irritate the horse creating safety issues ... properly fitted western saddle so it does not impact the comfort or performance of ...
(Date:12/5/2016)... , ... December 05, 2016 , ... “Life Will Never ... a supportive family and friends. “Life Will Never Be The Same” is the creation ... course in writing children's books and holds a degree in Christian religion and philosophy ...
(Date:12/5/2016)... ... December 05, 2016 , ... Sabah Shah MD, MBA has joined the Retina Group of ... York was founded by James M. Maisel, MD and has been providing tertiary medical and ... followed a legacy of surpassing expectations amongst her peers. Growing up in a family ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... ensure moisture measurements are consistently correct. However, regular performance testing is often ... TOLEDO offers a solution: SmartCal™ . This innovative test substance offers ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... LAKE OSWEGO, Ore. , Dec. 5, 2016 /PRNewswire/ ... in the BioInsight clinical study. The study evaluates the ... 2 insertion procedure in an office setting. ... ProMRI ® technology that is placed underneath a ... atrial fibrillation and syncope (fainting). Atrial fibrillation is a ...
(Date:12/5/2016)... Calif. , Dec. 5, 2016 Sanovas, ... technology accelerator, announced today the launch of its wholly owned ... Logo - http://photos.prnewswire.com/prnh/20161202/445250LOGO   Logo - http://photos.prnewswire.com/prnh/20161202/445251LOGO ... ... There ...
(Date:12/5/2016)... Dec. 5, 2016  Wellbridge Health and Gateway Health proudly ... solutions to Medicare and Medicaid plan members with specific high ... the unique needs of this group of consumers, Wellbridge combines ... philosophies to provide insight into members, daily behaviors and lifestyle. ... , , ...
Breaking Medicine Technology: